-
-
-
-
-
-
-
Belite Bio completes enrollment in DRAGON II trial for Stargardt disease
-
-
-
-
-
-
-
Mizuho Starts Belite Bio, Inc, ADR (BLTE) at Neutral
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
-
-
-
-
-
-
Belite Bio (BLTE) Tops Q1 EPS by 10c
-
-
-
-
-
-
-
Belite Bio (BLTE) Tops Q3 EPS by 1c
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

